Ivelina Gueorguieva

A Phase II randomized study of galunisertib monotherapy or galunisertib plus lomustine compared with lomustine monotherapy in patients with recurrent glioblastoma

Alba A. Brandes, Santosh Kesari, Juan Manuel Sepúlveda-Sánchez et al. · Neuro-Oncology · 2016 · 264 citations · Full text

Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer

Davide Melisi, Rocio García‐Carbonero, Teresa Macarulla et al. · British Journal of Cancer · 2018 · 262 citations · Full text

A Phase 2 Study of Galunisertib (TGF-β1 Receptor Type I Inhibitor) and Sorafenib in Patients With Advanced Hepatocellular Carcinoma

Robin Kate Kelley, Edward Gane, Eric Assénat et al. · Clinical and Translational Gastroenterology · 2019 · 232 citations · Full text

First-in-Human Dose Study of the Novel Transforming Growth Factor-β Receptor I Kinase Inhibitor LY2157299 Monohydrate in Patients with Advanced Cancer and Glioma

Jordi Rodón, Michael A. Carducci, Juan Manuel Sepúlveda-Sánchez et al. · Clinical Cancer Research · 2014 · 229 citations · Full text

Safety and activity of the TGFβ receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer

Davide Melisi, Do‐Youn Oh, Antoine Hollebecque et al. · Journal for ImmunoTherapy of Cancer · 2021 · 178 citations · Full text